4-HO-MET

4-HO-MET
Clinical data
Other names	4-OH-MET; 4-Hydroxy-N-methyl-N-ethyltryptamine; Metocin; Methylcybin
Routes of; administration	Oral
Drug class	Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	US: Unscheduled; Schedule I controlled substance in Virginia
Pharmacokinetic data
Onset of action	≤30 minutes
Duration of action	4–6 hours
Identifiers
	IUPAC name 3-{2-[Ethyl(methyl)amino]ethyl}-1H-indol-4-ol;
CAS Number	77872–41–4;
PubChem CID	21786582;
ChemSpider	10513072;
UNII	6RN01B78NY;
CompTox Dashboard (EPA)	DTXSID70228491 ;
Chemical and physical data
Formula	C13H18N2O
Molar mass	218.300 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(C)CCc2c[nH]c1cccc(O)c12;
	InChI InChI=1S/C13H18N2O/c1-3-15(2)8-7-10-9-14-11-5-4-6-12(16)13(10)11/h4-6,9,14,16H,3,7-8H2,1-2H3; Key:ORWQBKPSGDRPPA-UHFFFAOYSA-N;

4-HO-MET, also known as 4-hydroxy-N-methyl-N-ethyltryptamine, as well as metocin or methylcybin, is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families related to psilocin (4-HO-DMT). It is taken orally.

The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT_2A receptor. It is a close structural analogue of psilocin (4-HO-DMT) and is the 4-hydroxyl analogue of methylethyltryptamine (MET).

4-HO-MET was discovered by Alexander Shulgin in the 1970s. It was first described in the literature by David Repke and colleagues in 1981. The drug was encountered as a novel recreational and designer drug by 2008.